Andrew Left convicted in Citron short-selling fraud case in Los Angeles

Andrew Left was convicted on 13 of 17 counts in Los Angeles after a three-week trial that turned a familiar Wall Street tactic, public short selling, into a test of how far market skepticism can go before it becomes fraud. Jurors deliberated for two days before returning the verdict against the founder of Citron Research, and prosecutors said Left earned more than $20 million from the trading strategy at issue.

The case began with a sweeping federal indictment on July 25, 2024, in the Central District of California. The U.S. Department of Justice charged Left with one count of securities fraud scheme, 16 counts of securities fraud and one count of making false statements to federal investigators, alleging a long-running market-manipulation scheme that brought in at least $16 million. Prosecutors said Left used Citron Research, his online persona and publishing platform, to issue public investment recommendations while falsely suggesting his trading positions matched those calls.

The Securities and Exchange Commission separately accused Left and Citron Capital LLC of running a $20 million, multi-year fraud scheme that relied on false and misleading statements made at least 26 times across 23 companies. The SEC said the challenged conduct stretched from about March 2018 through December 2020 and claimed the stocks moved more than 12% on average after Left’s recommendations. It described the pattern as a bait-and-switch, with Left publicly recommending positions and then quickly reversing course to profit from the price swings. The complaint also said Citron Research had more than 100,000 followers on Twitter.

The verdict lands at a moment when activist short sellers already face intense political and corporate scrutiny. Left built a reputation as one of the most visible names in the field, a securities analyst and trader who appeared frequently on CNBC, Fox Business and Bloomberg Television and took on companies including GameStop, Valeant Pharmaceuticals, China Evergrande and Shopify. Supporters of short sellers argue they help expose fraud and inflated valuations; critics call the practice a vehicle for manipulation and reputational damage.

Left said outside the courtroom that he thought the jury got it wrong and suggested he may appeal. He remains free pending sentencing, which is set for Aug. 31, 2026. However the case ends, it is likely to shape how aggressively research firms publish negative calls, and how sharply regulators and companies draw the line between pointed commentary and market manipulation.